RPIB9 inhibitors belong to a specialized class of chemical compounds that are characterized by their unique ability to interact with specific biological targets, typically enzymes or receptor proteins, to induce a change in their biochemical activity. The term "RPIB9" itself is an abbreviation that stands for a particular molecular target, which these inhibitors are designed to engage with at a cellular or molecular level. The inhibitors function by binding to their target, which is often a crucial component in a complex biological pathway. This binding action can alter the conformation of the target molecule, which can result in the modulation of its activity. The interaction between RPIB9 inhibitors and their targets is highly specific, a specificity that arises from the precise molecular recognition that is a hallmark of their chemical structure. The inhibitors are typically composed of a scaffold that is complementary to the active site or the binding region of their target molecule, and this complementarity is often enhanced by the presence of side chains or functional groups that can form non-covalent interactions such as hydrogen bonds, ionic interactions, or hydrophobic contacts.
The development and study of RPIB9 inhibitors are driven by the pursuit of understanding fundamental biochemical processes at a deeper level. These compounds are valuable tools in experimental research, where they can be used to probe the function of the RPIB9 target in isolated systems, such as in vitro assays, or within the context of a living organism. By inhibiting the function of their target, RPIB9 inhibitors can help elucidate the role that the target plays in complex biological pathways. Such insights can be pivotal for mapping out the intricate networks of interactions that sustain cellular function and for unraveling the mechanisms underlying the regulation of these pathways. Moreover, the specificity of RPIB9 inhibitors makes them particularly useful in dissecting the contributions of individual components within a pathway, thus enabling a more nuanced understanding of biological processes at the molecular level. In the realm of biochemistry and molecular biology, RPIB9 inhibitors represent a powerful means by which scientists can manipulate and study the dynamics of life-sustaining reactions and the molecular architecture that orchestrates these processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that leads to cell cycle arrest. RPIB9 function is affected as the cell cycle regulation is crucial for its activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor that disrupts the MAPK/ERK signaling pathway. RPIB9, being associated with signal transduction, could have its function impaired when this pathway is inhibited. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that hampers the PI3K/AKT pathway, potentially leading to a reduction in RPIB9 activity which may be PI3K/AKT dependent. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which can lead to downregulation of protein synthesis, indirectly affecting RPIB9 protein levels and function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor which could lead to increased cellular stress and potentially alter RPIB9 levels as part of the unfolded protein response. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR inhibitor which may impact RPIB9 by disrupting downstream signaling pathways that RPIB9 is involved in. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that could modulate the stress response pathways, potentially diminishing RPIB9's involvement in these pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
An inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to ER stress which could affect RPIB9's function if it is ER-associated. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that, by inactivating MAPK/ERK signaling, may indirectly inhibit RPIB9 if it relies on this pathway for activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor that could prevent the activation of MAPK/ERK pathway, potentially leading to decreased RPIB9 activity. | ||||||